Novogenia AG, an international healthcare company specializing in human genetics, has announced the U.S. launch of its new MGT Plus methylation test. This move marks a significant step in the company's expansion into the American market, strengthening its collaboration with U.S. partner 10X Health. The test offers a more comprehensive analysis of methylation processes, which are crucial to numerous metabolic and regulatory functions in the body.
Methylation is a fundamental biochemical process that influences the function and processing of various biological molecules, including vitamins and neurotransmitters. While existing commercial tests typically analyze a limited number of genes, the MGT Plus test covers 27 genes across six interconnected biological pathways: energy and nutrient metabolism, stress and neurotransmitter regulation, and vascular, immune, and cellular health. This broader scope provides a more detailed picture of methylation-related metabolic pathways, enabling more precise insights for personalized prevention and health strategies.
According to Dr. Daniel Wallerstorfer, CEO of Novogenia AG, "With MGT Plus, we are enabling a more comprehensive understanding of biochemical methylation processes. The significantly expanded scope of analysis provides deeper insights into genetic factors involved in methylation-related metabolic pathways in the body, creating new opportunities for more personalized prevention and health strategies." He added that the collaboration with 10X Health underscores their commitment to making scientific innovations accessible internationally.
The launch comes at a time when the global direct-to-consumer testing market is experiencing rapid growth. In 2025, the market was valued at approximately $4.7 billion and is projected to exceed $16.0 billion by 2033. Genetic testing represents the largest segment, accounting for over 40% of the market. North America leads this sector, contributing to around 50% of the global market volume in 2025, driven by increasing consumer interest in personalized health information and preventive care.
Novogenia's expansion into the U.S. with the MGT Plus test positions the company to capitalize on this growing demand. The test's enhanced analytical capabilities could offer healthcare providers and consumers a more thorough understanding of genetic factors affecting health, potentially leading to more tailored interventions. As the market for direct-to-consumer genetic testing expands, innovations like MGT Plus are likely to play a key role in shaping the future of personalized medicine.
For more information about Novogenia and its products, visit Novogenia's website.
